# US 2010/0137251 A1 · Functional Role for Cannabinoids in Autonomic Stability During Sleep

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137251 A1
- Document ID: US20100137251A1
- Status: Published application
- Kind: A1
- Application number: 12/631,359
- Filed: 2009-12-04
- Published: 2010-06-03
- Earliest claimed: 2001-04-06
- Assignees: The Board of Trustees of the University of Illinois
- Inventors: David W. Carley; Miodrag Radulovacki
- Web page: https://patentgrep.com/patent/US20100137251A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/195: having an amino group
- A61K 31/35: having six-membered rings with one oxygen as the only ring hetero atom
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of cannabimimetic agents and combinations thereof.

## Claims

### Claim at position 1

-6. (canceled)

### Claim 7

A method of ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of an agent that inhibits cannabinoid metabolism or a combination of agents that inhibit cannabinoid metabolism.

### Claim 8 (depends on 7)

The method of claim 7 wherein the sleep-related breathing disorder is selected from the group consisting of obstructive sleep apnea syndrome, obstructive sleep apnea/hypopnea syndrome, upper airway resistance syndrome, apnea of prematurity, congenital central hypoventilation syndrome, obesity hypoventilation syndrome, central sleep apnea syndrome, Cheyne-Stokes respiration, and snoring.

### Claim 9 (depends on 8)

The method of claim 8 wherein the inhibitor of cannabinoid metabolism is selected from the group consisting of phenylmethylsulphonyl fluoride, palmitylsulphonyl fluoride, stearylsulphonyl fluoride, methyl arachidonyl fluorophosphonate, and O-1887.

### Claim 10

A method of ameliorating a sleep-related breathing disorder comprising administering to a patient in need thereof an effective amount of an agent that inhibits endocannabinoid membrane transport or a combination of agents that inhibit endocannabinoid membrane transport.

### Claim 11 (depends on 10)

The method of claim 10 wherein the sleep-related breathing disorder is selected from the group consisting of obstructive sleep apnea syndrome, obstructive sleep apnea/hypopnea syndrome, upper airway resistance syndrome, apnea of prematurity, congenital central hypoventilation syndrome, obesity hypoventilation syndrome, central sleep apnea syndrome, Cheyne-Stokes respiration, and snoring.

### Claim 12 (depends on 11)

The method of claim 11 wherein the inhibitor of endocannabinoid membrane transport is selected from the group consisting of AM404, VDM11, and arvanil.

### Claim at position 8

-15. (canceled)
